Sygnature Discovery, am integrated drug discovery solutions provider, has appointed pharmaceutical executive Dr Charles Woler as Chair.
Dr Woler has held multiple key roles in the sector, including CEO at Roche France, Executive Chairman for Europe at SmithKline Beecham, and CEO at Cadus Pharmaceutical in the US.
As Chairman, Dr Woler will support Sygnature Discovery’s recruitment efforts, broaden its therapeutic areas, grow its presence in North America, and build on the potential of AI and machine learning in drug discovery.
He gained a PhD in Clinical Pharmacology from the University of Lyon and an MD from Université Paris Diderot (Paris VII), and has since spent more than 35 years in the pharmaceutical, biotech and medical sectors in Europe and North America.
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021.
Dr Charles Woler, Chairman at Sygnature Discovery, said: "I am a long-time admirer of Sygnature Discovery, having previously done due diligence on the company while considering investment possibilities when working in private equity, so I am thrilled to join such a successful, ambitious organisation.”
Dr Simon Hirst, CEO and founder of Sygnature Discovery, said: "We are very excited to be working with Charles in this new phase of investment. Charles has a wealth of pharmaceutical knowledge and experience in various leadership, R&D, sales and management positions across our industry.”
